Home/Filings/4/0000950170-25-015701
4//SEC Filing

Klee Justin B. 4

Accession 0000950170-25-015701

CIK 0001658551other

Filed

Feb 5, 7:00 PM ET

Accepted

Feb 6, 8:17 PM ET

Size

6.6 KB

Accession

0000950170-25-015701

Insider Transaction Report

Form 4
Period: 2025-02-05
Klee Justin B.
DirectorCo-Chief Executive Officer
Transactions
  • Exercise/Conversion

    Common Stock

    2025-02-05$1.57/sh+36,310$57,0073,201,243 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2025-02-0536,3100 total
    Exercise: $1.57Exp: 2025-02-26Common Stock (36,310 underlying)
Footnotes (1)
  • [F1]This option is fully vested and exercisable.

Documents

1 file

Issuer

Amylyx Pharmaceuticals, Inc.

CIK 0001658551

Entity typeother

Related Parties

1
  • filerCIK 0001898314

Filing Metadata

Form type
4
Filed
Feb 5, 7:00 PM ET
Accepted
Feb 6, 8:17 PM ET
Size
6.6 KB